X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs WYETH LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA WYETH LTD ABBOTT INDIA/
WYETH LTD
 
P/E (TTM) x 41.2 27.7 148.7% View Chart
P/BV x 9.8 5.3 182.6% View Chart
Dividend Yield % 0.7 1.3 55.5%  

Financials

 ABBOTT INDIA   WYETH LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
WYETH LTD
Mar-13
ABBOTT INDIA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs6,1101,044 585.0%   
Low Rs3,996818 488.5%   
Sales per share (Unadj.) Rs1,552.2298.6 519.9%  
Earnings per share (Unadj.) Rs188.857.2 329.8%  
Cash flow per share (Unadj.) Rs196.458.4 336.3%  
Dividends per share (Unadj.) Rs55.0017.00 323.5%  
Dividend yield (eoy) %1.11.8 59.6%  
Book value per share (Unadj.) Rs796.6249.5 319.3%  
Shares outstanding (eoy) m21.2522.72 93.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.1 104.4%   
Avg P/E ratio x26.816.3 164.5%  
P/CF ratio (eoy) x25.715.9 161.4%  
Price / Book Value ratio x6.33.7 169.9%  
Dividend payout %29.129.7 98.1%   
Avg Mkt Cap Rs m107,37621,157 507.5%   
No. of employees `0003.30.5 675.2%   
Total wages/salary Rs m3,937400 984.2%   
Avg. sales/employee Rs Th9,929.313,787.4 72.0%   
Avg. wages/employee Rs Th1,185.1813.0 145.8%   
Avg. net profit/employee Rs Th1,207.72,643.3 45.7%   
INCOME DATA
Net Sales Rs m32,9856,783 486.3%  
Other income Rs m1,170353 331.8%   
Total revenues Rs m34,1557,136 478.6%   
Gross profit Rs m5,2451,617 324.3%  
Depreciation Rs m16227 608.6%   
Interest Rs m386 694.5%   
Profit before tax Rs m6,2151,938 320.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m2,203632 348.4%   
Profit after tax Rs m4,0121,301 308.5%  
Gross profit margin %15.923.8 66.7%  
Effective tax rate %35.432.6 108.6%   
Net profit margin %12.219.2 63.4%  
BALANCE SHEET DATA
Current assets Rs m22,6556,984 324.4%   
Current liabilities Rs m6,6812,056 325.0%   
Net working cap to sales %48.472.6 66.7%  
Current ratio x3.43.4 99.8%  
Inventory Days Days6599 65.3%  
Debtors Days Days2924 121.8%  
Net fixed assets Rs m835244 342.0%   
Share capital Rs m213227 93.5%   
"Free" reserves Rs m16,7155,441 307.2%   
Net worth Rs m16,9285,668 298.7%   
Long term debt Rs m025 0.0%   
Total assets Rs m24,1627,901 305.8%  
Interest coverage x163.7353.3 46.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.9 159.0%   
Return on assets %16.816.5 101.4%  
Return on equity %23.722.9 103.3%  
Return on capital %36.934.0 108.5%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m36915 2,424.6%   
Fx outflow Rs m3,8072,677 142.2%   
Net fx Rs m-3,438-2,662 129.2%   
CASH FLOW
From Operations Rs m1,527923 165.4%  
From Investments Rs m-2,148317 -677.9%  
From Financial Activity Rs m-1,024-481 213.0%  
Net Cashflow Rs m-1,646759 -216.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.1 146.8%  
Indian inst/Mut Fund % 7.9 11.3 69.9%  
FIIs % 0.1 7.2 1.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 30.4 56.3%  
Shareholders   18,270 21,978 83.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

PFIZER share price has hit an all time high at Rs 3,090 . The BSE HEALTHCARE Index is up by 1.0%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER and ABBOTT INDIA . The top losers include PFIZER and GSK PHARMA (down 0.1%).

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 17, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - ALEMBIC PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS